HC Wainwright Has Bearish Forecast for DNLI FY2024 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - HC Wainwright decreased their FY2024 earnings estimates for shares of Denali Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($2.86) per share for the year, down from their prior estimate of ($2.47). HC Wainwright currently has a "Buy" rating and a $90.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Denali Therapeutics' Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($3.17) EPS, FY2026 earnings at ($0.69) EPS and FY2028 earnings at $3.98 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) EPS.

Several other equities analysts also recently weighed in on the company. Citigroup boosted their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Cantor Fitzgerald downgraded shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, Bank of America lifted their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Denali Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $38.90.

Denali Therapeutics Stock Up 0.7 %

Shares of DNLI traded up $0.23 during mid-day trading on Monday, reaching $31.58. 797,116 shares of the company's stock were exchanged, compared to its average volume of 1,069,696. The company has a 50-day simple moving average of $27.95 and a two-hundred day simple moving average of $23.73. The company has a market cap of $4.54 billion, a price-to-earnings ratio of -11.44 and a beta of 1.40. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after acquiring an additional 1,847 shares during the period. CWM LLC lifted its stake in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after buying an additional 654 shares during the period. Quest Partners LLC acquired a new stake in Denali Therapeutics during the third quarter worth about $73,000. Headlands Technologies LLC bought a new position in Denali Therapeutics during the first quarter valued at about $88,000. Finally, Assetmark Inc. lifted its position in shares of Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after acquiring an additional 580 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the transaction, the director now directly owns 29,096 shares in the company, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Steve E. Krognes sold 30,000 shares of the company's stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares of the company's stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the firm's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.